Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leading treatment, Paxlovid.
The world, however, has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the price. The sales of its two Covid blockbusters may decline over 60% in 2023, after generating a combined $57 billion in revenue during 2022. And there is considerable uncertainty about demand for both in the coming years.
Source: finance.yahoo.com
Related posts:
Snap 'is going through a near-death experience,' analyst explains
It will take years for the oil and gas market to recover from the 'mother of all shocks,' Harvard ec...
‘We could barely afford a babysitter in New York City.’ But we bought a gorgeous, $340,000 house in ...
Federal Reserve raises interest rate by 0.50 percentage points to curb inflation but sees steeper hi...
Nvidia's CEO Just Explained Why This Is the Artificial Intelligence (AI) Chip Stock to Own